Active, not recruitingPhase 3NCT03995108
Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome
Studying WHIM syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- X4 Pharmaceuticals
- Principal Investigator
- Chief Medical OfficerX4 Pharmaceuticals
- Intervention
- Mavorixafor(drug)
- Enrollment
- 31 enrolled
- Eligibility
- 12 years · All sexes
- Timeline
- 2019 – 2025
Study locations (23)
- University of California San Diego Health/Rady Children's Hospital, San Diego, California, United States
- California Dermatology Institute, Thousand Oaks, California, United States
- University of Iowa, Iowa City, Iowa, United States
- Johns Hopkins University Medical Center, Baltimore, Maryland, United States
- University of Texas Southwestern Medical Center, Dallas, Texas, United States
- University of Washington Medical Center, Seattle, Washington, United States
- Wesley Hospital, Auchenflower, Queensland, Australia
- Children's Health Queensland Hospital, South Brisbane, Queensland, Australia
- Medical University of Vienna - Medizinische Universität Wien, Vienna, Austria
- Aarhus University Hospital, Aarhus, Denmark
- CHU de Lyon, Institut d'Hematologie et d'Oncologie Pediatrique, Lyon, Rhne, France
- CHU Paris Est, Hôpital d'Enfants Armand-Trousseau, Paris, France
- Hopital Necker-Enfants Malades, Paris, France
- University of Debrecen, Affiliated Department of Infectology, Debrecen, Hajdú-Bihar, Hungary
- HaEmek Medical Center, Afula, Israel
- +8 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03995108 on ClinicalTrials.gov